BBT-877 is under development as a treatment for various fibrotic diseases.

  • About the drug candidate

    BBT-877 is an orally administered autotaxin enzyme inhibitor which is under development as a treatment for various fibrotic diseases such as idiopathic pulmonary fibrosis (IPF).

    Autotaxin is an enzyme that converts lysophosphatidylcholine (LPC), a type of fat in the human body, into lysophosphatidic acid (LPA), a molecule which is known to lead to various types of fibrosis. LPA produced by autotaxin is known to bind to receptors in cells and induce various physiological activities, such as neovascularization, sclerosis, tumorigenesis and tumor metastasis.

    BBT-877 is a small-molecule compound that suppresses inflammation and sclerosis by reducing LPA production through the selective inhibition of autotaxin.

    During pre-clinical studies on animal disease models with bleomycin induced pulmonary failure, BBT-877 showed superior results in both the Ashcroft score and collagen deposition when compared to nintedanib’s positive control group and GLPG1690, a now-discontinued idiopathic pulmonary fibrosis program of Galapagos NV. (Presented at IPF Summit 2018)

    During the US-based Phase 1 clinical trial, BBT-877 showed dose proportionate systemic exposure. All dose levels were well tolerated with no serious adverse events (SAEs) reported. The data on LPA inhibition in the multi-ascending dose study showed that 100mg and 200mg twice daily dosages induced LPA inhibition of up to 90%. The Phase I clinical trial results were presented at the postersession of the European Respiratory Society Annual Conference 2019.

    With these pre-clinical and clinical results, Bridge Biotherapeutics signed a collaboration and global license agreement with Boehringer Ingelheim, a leading pharmaceutical company in the idiopathic pulmonary fibrosis treatment market, on July 17, 2019 (upfront and near-term payments equating to €45mn with eligibility to receive potential milestone payments and royalties exceeding €1.1bn). In November 2020, the two companies mutually agreed to terminate the Collaboration and License Agreement.

    Bridge Biotherapeutics continues to commit to the further development of BBT-877 in order to help patients with idiopathic pulmonary fibrosis. The company submitted a type C meeting request to the US FDA before initiating its first-in-patient, Phase II study in patients with idiopathic pulmonary fibrosis.

    Based on in vitro comet assay data submitted by Bridge Biotherapeutics, the US FDA recommended additional studies including an in vivo comet assay analyzed by Transmission Electron Microscopy (TEM) and a drug interaction study between BBT-877 and existing standard of care treatments, nintedanib and pirfenidone.

    In addition to idiopathic pulmonary fibrosis, the company is exploring indication expansion opportunities for BBT-877 in progressive fibrosing interstitial lung diseases (PF-ILD) and various carcinomas.

    Bridge Biotherapeutics acquired the exclusive global license for BBT-877 from LegoChem Biosciences in May 2017.

    Our research results were presented at the following conferences and can be downloaded by clicking the link down below.

    • Event
      Date of Presentation
    • Event

      European Respiratory Society 2019

      Date of Presentation

      2019년 09월 29일

    • Event

      American Thoracic Society 2019

      Date of Presentation

      2019년 05월 20일

    • Event

      IPF Summit 2018

      Date of Presentation

      2018년 08월 22일

  • Clinicalstudy information

  • Ask about the clinical studies

  • What is idiopathicpulmonary fibrosis?

    Idiopathic pulmonary fibrosis (IPF) is a type of interstitial lung disease which results in pulmonary fibrosis for unknown reasons, leading to scarring, shortness of breath, dry cough and gradual loss of lung function.

    Idiopathic pulmonary fibrosis affects 5 million people globally and has an estimated prevalence of 12 per 100,000 persons. Those over 60 are most commonly affected and the average life expectancy following diagnosis is approximately 4 years.

    More information available on NIH (U.S. National Library of Medicine)